Global Opioid-Induced Constipation Treatment Market 2024 - By Growth Opportunities, Future Insights, Regional Segments, Latest Innovations And Forecast To 2033

Global opioid-induced constipation treatment market size is expected to reach $2.31 Bn by 2028 at a rate of 6.8%, segmented as by drug class, laxatives, peripherally acting µ-opioid receptor antagonists, serotonin receptor agonists, prostaglandin

Aug 28, 2024 - 16:38

Global Opioid-Induced Constipation Treatment Market 2024 - By Growth Opportunities, Future Insights, Regional Segments, Latest Innovations And Forecast To 2033

Opioid-induced constipation (OIC) treatment refers to the various approaches and medications used to manage constipation caused by the use of opioid medications. These treatments aim to alleviate the symptoms of constipation without compromising the pain-relieving effects of opioids, thereby improving the patient's overall quality of life and maintaining effective pain management with both pharmacological with non-pharmacological approaches.

Sizing and Forecast

The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.

The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to accelerated drug approval initiatives, increasing use of opioid analgesic prescriptions, surging expenditure on the R And D of novel treatments, and an increase in development of biologics. Major trends in the forecast period include patient education and awareness, the emergence of targeted therapies, non-pharmacological interventions, biotechnology innovations, and increased investment.

Order your report now for swift delivery, visit the link:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Segmentation & Regional Insights

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting μ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

North America was the largest region in the opioid-induced constipation treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Major Driver Impacting Market Growth

The rise in the administration of opioids for cancer and non-cancer pain is expected to propel the growth of the opioid-induced constipation treatment market going forward. Cancer pain refers to pain associated with cancer and its treatment, while non-cancer pain refers to pain from conditions unrelated to cancer. Administration of opioids for cancer and non-cancer pain is driven by the need to effectively manage moderate to severe pain, considering factors such as the intensity and duration of pain, patient response to other treatments, and the overall goal of improving quality of life while minimizing potential risks of addiction and side effects. Opioid-induced constipation (OIC) treatment helps patients with cancer and non-cancer pain by relieving constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, in April 2023, according to the Center for Disease Control and Prevention (CDC), a US-based national public health agency, during 2021, approximately 20.9% of U.S. adults (51.6 million people) reported experiencing chronic pain, and 6.9% (17.1 million people) experienced high-impact chronic pain, which significantly limits daily activities. Therefore, the rise in the administration of opioids for cancer and non-cancer pain is driving the growth of the opioid-induced constipation treatment market.

Key Industry Players

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

The opioid-induced constipation treatment market report table of contents includes:

1. Executive Summary

2. Opioid-Induced Constipation Treatment Market Characteristics

3. Opioid-Induced Constipation Treatment Market Trends And Strategies

4. Opioid-Induced Constipation Treatment Market - Macro Economic Scenario

5. Global Opioid-Induced Constipation Treatment Market Size and Growth

.............................

32. Global Opioid-Induced Constipation Treatment Market Competitive Benchmarking

33. Global Opioid-Induced Constipation Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Opioid-Induced Constipation Treatment Market

35. Opioid-Induced Constipation Treatment Market Future Outlook and Potential Analysis

36. Appendix